BOLD Boundless Bio: Net earnings per share growth forecast for next year
The history of consensus earnings estimates for the coming year demonstrates how Boundless Bio, Inc. (BOLD) integrates ESG principles into genetic research, ensuring bioethics and environmental sustainability. A team of elite scientists, motivated by stock options, is developing innovative therapies against extrachromosomal DNA. Meanwhile, the 61.30 level serves as a critical benchmark, as the company currently lacks commercial products and relies on venture capital.
BOLD (boundlessbio.com): analytical breakdowns and indicator data
- price and consensus price forecast:
- company stock capitalization data:
- company book value details:
- debt and liquidity data:
Total Debt to Capital Boundless Bio, Inc.|BOLD - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Boundless Bio|BOLD - Company Cumulative Debt|Debt to Book Value Boundless Bio|BOLD - Company Long-Term Loans and Borrowings|Company Short-Term Debts Boundless Bio|Quick Liquidity boundlessbio.com
- earnings and market ratios statistics:
BOLD - Company Profit|Projected Future Earnings Boundless Bio, Inc.|BOLD - Price to Earnings Ratio|Projected Price to Earnings Boundless Bio, Inc.|BOLD - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Boundless Bio|BOLD - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Boundless Bio|BOLD - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months boundlessbio.com|BOLD - Earnings per share growth in current year|Earnings growth forecast for next year Boundless Bio, Inc.
Fundamental company analysis:Boundless Bio, Inc
This metric measures the expected percentage growth in earnings per share (EPS), consolidating analyst forecasts for future business profitability. By using the benchmark of Boundless Bio, Inc. (BOLD) EPS dynamics for the coming year, an investor separates the fundamental trend from short-term noise, capturing the current value of 61.30. For Boundless Bio, Inc. (BOLD), this metric reflects market confidence in the commercial success of innovative ecDNA inhibitors for the therapy of aggressive tumors.
Competitor analysis for Boundless Bio, Inc.
Net earnings per share growth forecast for next year Tempus AI, Inc|Qiagen Corp (QGEN) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Ionis Pharmaceuticals (IONS)|Consensus forecast of earnings per share growth for next year repligen.com|Avidity Biosciences, Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year CRSP|Sema4 - Earnings growth forecast for next year|RARE: Net earnings per share growth forecast for next year|BEAM: Earnings growth forecast for next year|SRPT - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Twist Bioscience, Inc.|Expected net earnings per share growth next year 10x Genomics Inc TXG|Expected earnings per share growth for next year NTLA (Intellia)|STOK (Stoke Corp) - Expected earnings per share trend next year|Earnings growth forecast for next year BLFS (BioLife Solutions, Inc.)|Consensus forecast of earnings per share growth for next year wavelifesciences.com (WVE)|MAZE - Net earnings per share growth forecast for next year|SION (Sionna Therapeutics, Inc.) - Projected earnings per share growth rate for next year|PRME: Earnings growth forecast for next year|Expected earnings per share growth for next year Taysha Corp|Expected earnings per share growth for next year QURE|meiragtx.com (MGTX) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year RGNX|Net earnings per share growth forecast for next year SLDB (Solid Biosciences Inc)|Net earnings per share growth forecast for next year Ocugen Corp OCGN|PacBio Corp (PACB) - Expected net earnings per share growth next year|BNTC - Net earnings per share growth forecast for next year|DSGN: Net earnings per share growth forecast for next year|RCKT: Earnings growth forecast for next year|Projected earnings per share growth rate for next year FDMT|LXEO (Lexeo Therapeutics Inc.) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year KRRO (Korro Bio, Inc)|Net earnings per share growth forecast for next year Editas Medicine, Inc. (EDIT)|silence-therapeutics.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year PRQR (ProQR Therapeutics)|Earnings growth forecast for next year Codexis Inc CDXS|Sangamo - Earnings growth forecast for next year|NAUT: Net earnings per share growth forecast for next year|Metagenomi, Inc. (MGX) - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year Precision BioSciences Inc. (DTIL)|Expected earnings per share growth for next year GBIO|Earnings growth forecast for next year Exicure Corp|Net earnings per share growth forecast for next year Imunon, Inc. (IMNN)|phiopharma.com - Projected earnings per share growth rate for next year|Earnings growth forecast for next year MBIO (Mustang Bio)|RNAZ: Projected earnings per share growth rate for next year|BNGO - Net earnings per share growth forecast for next year|APDN: Net earnings per share growth forecast for next year|BLUE: Earnings growth forecast for next year|Expected net earnings per share growth next year ImmunoPrecise Antibodies Ltd. (IPA)|Net earnings per share growth forecast for next year Omega Therapeutics|singulargenomics.com (OMIC) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Regulus Therapeutics Inc. (RGLS)|Consensus forecast of earnings per share growth for next year Syros Pharmaceuticals Inc.|Codex DNA - Expected earnings per share growth for next year|Expected earnings per share trend next year TCON|Unity Biotechnology - Earnings growth forecast for next year
